Table 1 Phase II trials: SVR Rate with DAA in HCVG 2-3 naives and experienced (NOT HEAD TO HEAD STUDIES)

DAA	Class	DAA Duration	PR Duration	N	SVR 4*/24 Naives	SVR 4 experienced
PR+GS-7977	NS5bPolI	12 wk 12 wk 12 wk	12 wk 8 wk 4 wk	11 10 9	11/11 10/10 10/10
GS-7977 + R	Ns5bPolI	12 wk	0	11	11/11
GS-7977+ R	Ns5bPolI	12 wk	0	25		12/15
GS7977 + Daclatasvir + R	NNS5bPolI + NS5aPolI + R	24 wk 24 wk	0 0	30 14	28/30* 11/14*

Abbreviations: DAA: Directly Acting Antiviral; NS5b PolI : NS5b polymerase inhibitor; NS5a Polymerase Inhibitor; PR Pegylated Interferon combined with Ribavirin; wk: week; SVR: Sustained Virologic Response; SVR 4: HCVRNA below the level of detection with Roche TaqMan assay 4 weeks after treatment withdrawal; SVR 24: HCVRNA below the level of detection with Roche TaqMan assay 24 weeks after treatment withdrawal

ISSN: 1471-2334